BioSig Technologies Donates to American Heart Association in Sponsorship of American Heart Month
Company Hopes to Bring Greater Awareness to America’s Leading Health Risk
Minneapolis, MN, Feb. 10, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, announced that the company has made a donation to the American Heart Association as in order to help bring awareness to American Heart Month this February.
“Heart disease is the leading cause of death for both men and women in the United States, accounting for approximately 1 in 4 deaths,” stated Mr. Gregory Cash, President and CEO of BioSig Technologies Inc. “BioSig is proud to help generate awareness about this incredibly important health matter. Going forward, we will continue to work with our partners in the healthcare industry as we strive to save lives and defeat heart disease. BioSig looks forward to introducing our proprietary PURE EP System this year which we believe will provide a significant tool for doctors in addressing the large and growing Atrial Fibrillation and Ventricular Tachycardia market.”
According to recent studies, there are approximately 6 million Americans suffering with atrial fibrillation and about 450,000 sudden deaths from ventricular arrhythmias. BioSig is committed to helping improve diagnoses and catheter ablation treatments for these complex heart rhythm disorders. The Company’s PURE EP System, is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used in identifying ablation targets.
About the American Heart Association
The American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, the organization now includes more than 22.5 million volunteers and supporters. They fund innovative research, fight for stronger public health policies, and provide critical tools and information to save and improve lives. Their nationwide organization includes 156 local offices and more than 3,000 employees. The American Stroke Association was created as a division in 1997 to bring together the organization’s stroke-related activities.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.
BioSig’s technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.
Data from the 2016 HRI Global Opportunities in Medical Devices & Diagnostics report shows the global Electrophysiology (EP) market revenues will grow nearly 10% annually, from currently $4 billion to approximately $6 billion by 2020 with accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020. Procedure growth in the United States alone is projected at an 11.0% annual rate, from 250,000 in 2015 to 422,000 in 2020; accompanied by an 11.7% growth in revenues, from $1.85 billion in 2015 to $3.220 billion in 2020.
BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center, and has performed pre-clinical studies at Mayo Clinic in Minnesota and Mount Sinai Hospital in NY. The company continues to perform research and development studies in the form of an Advanced Research Program at Mayo Clinic which began in June 2016. Other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute and UH Case Medical Center in Cleveland also play an important role in the PURE EP technology.
Investor Relations: Brian McLaughlin BioSig Technologies, Inc. bmclaughlin@biosigtech.com 917-370-9817 Robert Haag IRTH Communications BSGM@irthcommunications.com 866-976-4784
Released February 10, 2017
